Molecular biology of basal and squamous cell carcinomas

Advances in Experimental Medicine and Biology

Volumn 624, Issue , 2008, Pages 241-251

  Xie, Jingwu ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPAMINE; DOCETAXEL; GEFITINIB; SUNSCREEN; VITAMIN D; WART VIRUS VACCINE;

BASAL CELL CARCINOMA; CANCER INCIDENCE; CANCER PREVENTION; HEDGEHOG SIGNALING PATHWAY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; ANIMAL; CHROMOSOME ABERRATION; DISEASE MODEL; GENETICS; MOLECULAR BIOLOGY; MOUSE; MUTATION; SKIN TUMOR;

ERINACEIDAE;

ANIMALS; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; CHROMOSOME ABERRATIONS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MOLECULAR BIOLOGY; MUTATION; SKIN NEOPLASMS;

EID: 42949156232     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-77574-6_19     Document Type: Review

References (85)

1. Christcnson LJ, Borrowman TA, Vachon CM et al. Incidence of basal ceil and squamous cell carcinomas in a population yoimger than 40 years. JAMA 2005; 294:681-90.
2. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66.
3. Hahn H, Wicking C, Zaphiropoulous PG et al. Mutations of the himian homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996; 85:841-51.
4. Johnson RL, Rothman AL, Xie J et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996; 272:1668-71.
5. Epstein E. Genetic determinants of basal cell carcinoma risk. Med Pediatr Oncol 2001; 36:555-8.
6. Taipale J, Beachy PA. The Hedgehog and Wht signalling pathways in cancer. Nature 2001; 411:349-54.
7. Chuang PT, McMahon AP. Vertebrate Hedgehog signalling modulated by induction of a Hedgehogbinding protein. Nature 1999; 397:617-21.
8. Jia J, Jiang J. Decoding the Hedgehog signal in animal development. Cell Mol Life Sci 2006; 63:1249-65.
9. Rohatgi R, Milenkovic L, Scott MP. Patchcdl regulates hedgehog signaling at the primary cilium. Science 2007; 317:372-6.
10. Corbit KC, Aanstad P, Singla V et al. Vertebrate Smoothened functions at the primary cilium. Nature 2005; 437:1018-21.
11. Pasca di Magliano M, Hebrok M. Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer 2003; 3:903-11.
12. Gorlin RJ. Nevoid basal-cell carcinoma syndrome. Medicine (Baltimore) 1987; 66:98-113.
13. Gorlin RJ. Living history-biography: from oral pathology to craniofacial genetics. Am J Med Genet 1993; 46:317-34.
14. GorUn RJ, Goltz RW. Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. A syndrome. N Engl J Med 1960; 262:908-12.
15. Gailani MR, Bale SJ, LeflFell DJ et al. Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell 1992; 69:111-7.
16. Gailani MR, Stahle-Backdahl M, Leffell DJ et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet 1996; 14:78-81.
17. Goodrich LV, Johnson RL, Milenkovic L et al. Conservation of the hedgehog/patched signaling pathway from flies to mice: induction of a mouse patched gene by Hedgehog. Genes Dev 1996; 10:301-12.
18. Lindstrom E, Shimokawa T, Toftgard R et al. PTCH mutations: distribution and analyses. Hum Mutat 2006; 27:215-9.
19. Bale AE, Yu, KP. The hedgehog pathway and basal cell carcinomas. Hum Mol Genet 2001; 10:757-62.
20. Goodrich LV, Milenkovic L, Higgins KM et al. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997; 277:1109-13.
21. Hahn H, Wbjnowski L, Zimmer AM et al. Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat Med 1998; 4:619-22.
22. Aszterbaum M, Beech J, Epstein EH. Ultraviolet radiation mutagenesis of hedgehog pathway genes in basal cell carcinomas. J Investig Dermatol Symp Proc 1999; 4:41-5.
23. Xie J, Murone M, Luoh SM et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998; 391:90-2.
24. Lam CW, Xie J, To KF et al. A frequent activated smoothened mutation in sporadic basal cell carcinomas. Oncogene 1999; 18:833-6.
25. Reifenberger J, Wolter M, Knobbe CB et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol 2005; 152:43-51.
26. Reifenberger J, Wolter M, Weber RG et al. Missensc mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1998; 58:1798-803.
27. Couve-Privat S, Bouadjar B, Avril MF et al. Significantly high levels of ultraviolet-specific mutations in the smoothened gene in basal cell carcinomas from DNA repair-deficient xeroderma pigmentosum patients. Cancer Res 2002; 62:7186-9.
28. Xic J, Asztcrbaum M, Zhang X et al. A role of PDGFRalpha in basal cell carcinoma proliferation. Proc Natl Acad Sci USA 2001; 98:9255-9.
29. Athar M, Li C, Tang X et al. Inhibition of smoothened signaling prevents ultraviolet B-induced basal cell carcinomas through regulation of Fas expression and apoptosis. Cancer Res 2004; 64:7545-52.
30. Williams JA, Guicherit OM, Zaharian BI et al. Identification of a small molecule inhibitor of the hedgehog signaling pathway: effects on basal cell carcinoma-like lesions. Proc Natl Acad Sci USA 2003; 100:4616-21.
31. Bijlsma MF, Spek CA, Zivkovic D et al. Repression of smoothened by patched-dependent (pro-) vitamin D3 secretion. PLoS Biol 2006; 4:e232.
32. Kasper M, Schnidar H, Neill GW et al. Selective modulation of Hedgehog/GLI target gene expression by epidermal growth factor signaUng in human keratinocytes. Mol Cell Biol 2006; 26:6283-98.
33. Riobo NA, Haines GM, Emerson CP. Protein kinase C-delta and mitogen-activated protein/extracellular signal-regulated kinase-1 control GLI activation in hedgehog signaling. Cancer Res 2006; 66:839-45.
34. Riobo NA, Lu K, Ai X et al. Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling. Proc Natl Acad Sci USA 2006; 103:4505-10.
35. Kenney AM, Widlund HR, Rowitch DH. Hedgehog and PI-3 kinase signaling converge on Nmycl to promote cell cycle progression in cerebellar neuronal precursors. Development 2004; 131:217-28.
36. Bigelow RL, Jen EY, Delchedde M et al. Sonic hedgehog induces epidermal growth factor dependent matrix infiltration in HaCaT keratinocytes. J Invest Dermatol 2005; 124:457-65.
37. Riobo NA, Lu K, Emerson CP. Hedgehog signal transduction: signal integration and cross talk in development and cancer. Cell Cycle 2006; 5:1612-5.
38. Ji Z, Mei FC, Xie J et al. Oncogenic kras supresses GLIl degradation and activates hedgehog signaling pathway in pancreatic cancer cells. J Biol Chem 2007.
39. Sheng T, Chi S, Zhang X et al. Regulation of Glil localization by the cAMP/protein kinase A signaling axis through a site near the nuclear locaUzation signal. J Biol Chem 2006; 281:9-12.
40. Caserta TM, Kommagani R, Yuan Z et al. p63 overexpression induces the expression of Sonic Hedgehog. Mol Cancer Res 2006; 4:759-68.
41. Uziel T, Zindy F, Xie S et al. The tmnor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. Genes Dcv 2005; 19:2656-67.
42. Mimeault M, Johansson SL, Vankatraman G et al. Combined targeting of epidermal growth factor receptor and hedgehog signaUng by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. Mol Cancer Ther 2007; 6:967-78.
43. Quaedvlieg PJ, Tirsi E, Thissen MR et aL Actinic keratosis: how to differentiate the good firom the bad ones? Eur J Dermatol 2006; 16:335-9.
44. Takata M, Saida T. Early cancers of the skin: clinical, histopathological and molecular characteristics. Int J Clin Oncol 2005; 10:391-7.
45. Boukamp P. Nonmelanoma skin cancer: what drives tumor development and progression? Carcinogenesis 2005; 26:1657-67.
46. Tsai KY, Tsao H. The genetics of skin cancer. Am J Med Genet C Semin Med Genet 2004; 131C:82-92.
47. Ridky TW, Khavari PA. Pathways sufficient to induce epidermal carcinogenesis. Cell Cycle 2004; 3:621-4.
48. Smith-McCune K, Zhu YH, Hanahan D et al. Cross-species comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the himian cervix and K14-HPV16 transgenic mice. Cancer Res 1997; 57:1294-300.
49. Brown VL, Harwood CA, Crook T et al. pl6INK4a and pl4ARF tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma. J Invest Dermatol 2004; 122:1284-92.
50. Blokx WA, Ruiter DJ, Verdijk MA et al. INK4-ARF and p53 mutations in metastatic cutaneous squamous cell carcinoma: case report and archival study on the use of Ink4a-ARF and p53 mutation analysis in identification of the corresponding primary tumor. Am J Surg Pathol 2005; 29:125-30.
51. Blokx WA, de Jong EM, de Wilde PC et al. P16 and p53 expression in (pre)malignant epidermal tumors of renal transplant recipients and immunocompetent individuals. Mod Pathol 2003; 16:869-78.
52. Saridaki Z, Liloglou T, Zafiropoulos A et al. Mutational analysis of CDKN2A genes in patients with squamous cell carcinoma of the skin. Br J Dermatol 2003; 148:638-48.
53. Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2002; 2:910-7.
54. Pickering MT, Kowalik TF. Rb inactivation leads to E2F1-mediated DNA double-strand break accumulation. Oncogene 2006; 25:746-55.
55. Soufir N, Moles JP, Vilmer C et al. P16 UV mutations in human skin epithelial tumors. Oncogene 1999; 18:5477-81.
56. Giglia-Mari G, Sarasin A. TP53 mutations in human skin cancers. Hum Mutat 2003; 21:217-28.
57. Bolshakov S, Walker CM, Strom SS ct al. p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas. Clin Cancer Res 2003; 9:228-34.
58. Kim MY, Park HJ, Baek SC et al. Mutations of the p53 and PTCH gene in basal cell carcinomas: UV mutation signature and strand bias. J Dermatol Sci 2002; 29:1-9.
59. Ansarin H, Daliri M, Soltani-Arabshahi R. Expression of p53 in aggressive and non-aggressive histologic variants of basal cell carcinoma. Eur J Dermatol 2006; 16:543-7.
60. D'Errico M, Calcagnile AS, Corona R et al. p53 mutations and chromosome instability in basal cell carcinomas developed at an early or late age. Cancer Res 1997; 57:747-52.
61. Wiseman SM, Stoler DL, Anderson GR. The role of genomic instability in the pathogenesis of squamous cell carcinoma of the head and neck. Surg Oncol Clin N Am 2004; 13:1-11.
62. Perez-Losada J, Mao JH, Balmain A. Control of genomic instability and epithelial timior development by the p53-Fbxw7/Cdc4 pathway. Cancer Res 2005; 65:6488-92.
63. Duensing A, Duensing S. Guilt by association? p53 and the development of aneuploidy in cancer. Biochem Biophys Res Commun 2005; 331:694-700.
64. Pelisson I, Soler C, Chardonnct Y et al. A possible role for human papillomaviruses and c-myc, c-Ha-ras and p53 gene alterations in malignant cutaneous lesions from renal transplant recipients. Cancer Detect Prev 1996; 20:20-30.
65. Aziz MH, Manoharan HT, Verma AK. Protein kinase C epsilon, which sensitizes skin to sun's UV radiation-induced cutaneous damage and development of squamous cell carcinomas, associates with Stat3. Cancer Res 2007; 67:1385-94.
66. Quadros MR, Peruzzi F, Kari C et al. Complex regulation of signal transducers and activators of transcription 3 activation in normal and maUgnant keratinocytes. Cancer Res 2004; 64:3934-9.
67. Dudley AC, Thomas D, Best J et al. A VEGF/JAK2/STAT5 axis may partially mediate endotheUal cell tolerance to hypoxia. Biochem J 2005; 390:427-36.
68. Budunova IV, Perez P, Vaden VR et al. Increased expression of p50-NF-kappaB and constitutive activation of NF-kappaB transcription factors during mouse skin carcinogenesis. Oncogene 1999; 18:7423-31.
69. Loercher A, Lee TL, Ricker JL et al. Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res 2004; 64:6511-23.
70. Duffey DC, Chen Z, Dong G et al. Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression and tumor growth in vivo. Cancer Res 1999; 59:3468-74.
71. Verma AK, Wheeler DL, Aziz MH et al. Protein kinase Cepsilon and development of squamous cell carcinoma, the nonmelanoma human skin cancer. Mol Carcinog 2006; 45:381-8.
72. Bremner R, Kemp CJ, Balmain A. Induction of different genetic changes by different classes of chemical carcinogens during progression of mouse skin tumors. Mol Carcinog 1994; 11:90-7.
73. DiGiovanni J. Genetic factors controlling responsiveness to skin tumor promotion in mice. Prog Clin Biol Res 1995; 391:195-212.
74. Hirst GL, Balmain A. Forty years of cancer modelling in the mouse. Eur J Cancer 2004; 40:1974-80.
75. Rebel H, Mosnier LO, Berg RJ et al. Early p53-positive foci as indicators of tumor risk in ultravioletexposed hairless mice: kinetics of induction, effects of DNA repair deficiency and p53 heterozygosity. Cancer Res 2001; 61:977-83.
76. Rebel H, Kram N, Westerman A et al. Relationship between UV-induced mutant p53 patches and skin tumours, analysed by mutation spectra and by induction kinetics in various DNA-repair-deficient mice. Carcinogenesis 2005; 26:2123-30.
77. Ahsan H, Aziz MH, Ahmad N. Ultraviolet B exposure activates Stat3 signaling via phosphorylation at tyrosine705 in skin of SKHl hairless mouse: a target for the management of skin cancer? Biochem Biophys Res Commun 2005; 333:241-6.
78. Wakabayashi Y, Mao JH, Brown K et al. Promotion of Hras-induced squamous carcinomas by a polymorphic variant of the Patched gene in FVB mice. Nature 2007; 445:761-5.
79. Roth JA. Adenovirus p53 gene therapy. Expert Opin Biol Ther 2006; 6:55-61.
80. McCormick F. Cancer-specific viruses and the development of ONYX-015. Cancer Biol Ther 2003; 2:S157-60.
81. Lane DP, Lain S. Therapeutic exploitation of the p53 pathway. Trends Mol Med 2002; 8;S38-42.
82. Vassilev LT. p53 Activation by small molecules: application in oncology. J Med Chem 2005; 48:4491-9.
83. Sherr CJ, McCormick R The RB and p53 pathways in cancer. Cancer Cell 2002; 2:103-12.
84. Green CL, Khavari PA. Targets for molecular therapy of skin cancer. Scmin Cancer Biol 2004; 14:63-9.
85. Ozols RF, Herbst RS, Colson YL et al. Clinical cancer advances 2006: major research advances in cancer treatment, prevention and screening-a report from the American Society of Clinical Oncology. J Clin Oncol 2007; 25:146-62.